title: Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism.
abstract: Serum osteocalcin was measured in patients with idiopathic hypoparathyroidism or pseudohypoparathyroidism, before or during the treatment with active vitamin D3 (1,25(OH)2D3 or 1 alpha OHD3). Serum osteocalcin and plasma 1,25(OH)2D were decreased in 11 patients with idiopathic hypoparathyroidism before treatment (2.8 +/- 1.27 ng/ml, P less than 0.001 and 14.3 +/- 4.27 pg/ml, P less than 0.001, respectively). In 24 patients with idiopathic hypoparathyroidism during the treatment, serum osteocalcin and plasma 1,25(OH)2D were within the normal range (4.5 +/- 0.74 ng/ml and 25.7 +/- 5.69 pg/ml, respectively). In five patients with pseudohypoparathyroidism before treatment, plasma 1,25(OH)2D was decreased (15.6 +/- 10.6 pg/ml, P less than 0.001) but serum osteocalcin was normal (7.8 +/- 1.66 ng/ml). In nine patients with pseudohypoparathyroidism during the treatment with active vitamin D3, serum osteocalcin and plasma 1,25(OH)2D were normal (6.8 +/- 1.47 ng/ml and 27.2 +/- 6.0 pg/ml, respectively). Serum PTH in pseudohypoparathyroidism was increased before treatment (0.70 +/- 0.34 ng/ml, P less than 0.05) and was normal during the treatment (0.50 +/- 0.13 ng/ml). In idiopathic hypoparathyroidism, the active vitamin D3 increased serum osteocalcin without PTH. In pseudohypoparathyroidism, PTH may increase serum osteocalcin or modulate the effect of active vitamin D3 on serum osteocalcin.
authors.affiliation: Second Department of Internal Medicine, Tohoku University, School of Medicine, Sendai, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Mizunashi
authors.forename: Y
authors.initials: Y
authors.lastname: Furukawa
authors.forename: R
authors.initials: R
authors.lastname: Miura
authors.forename: S
authors.initials: S
authors.lastname: Yumita
authors.forename: H E
authors.initials: HE
authors.lastname: Sohn
authors.forename: K
authors.initials: K
authors.lastname: Yoshinaga
mesh_terms: D000328:Adult; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D002135:Calcium-Binding Proteins / Q000097:blood*; D002762:Cholecalciferol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007011:Hypoparathyroidism / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin; D010281:Parathyroid Hormone / Q000097:blood / Q000627:therapeutic use*; D010758:Phosphorus / Q000097:blood; D011547:Pseudohypoparathyroidism / Q000097:blood* / Q000188:drug therapy
chemical_list: D002135:Calcium-Binding Proteins; D010281:Parathyroid Hormone; D015675:Osteocalcin; D002762:Cholecalciferol; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium